

TKI resistance in CML cell lines: Investigating resistance pathways

Carine Tang

The Melissa White Laboratory
Centre for Cancer Biology and
SA Pathology

&

The Faculty of Health Sciences
Department of Medicine
The University of Adelaide
South Australia

Thesis submitted to the University of Adelaide
in candidature for the degree of Doctor of Philosophy
2011

Supervisors: Prof. Timothy Hughes^{1,2} & A/Prof. Deborah White^{1,2}

1 The Melissa White Laboratory, Division of Haematology, IMVS

2 Centre for Cancer Biology, Adelaide, Australia

Table of Contents

Declaration	12
Acknowledgements	13
Glossary	15
Abstract	18
Chapter 1:	20
Introduction	20
1.1 Chronic myeloid leukaemia	21
1.2 The Philadelphia chromosome and BCR-ABL	21
1.2.1 BCR-ABL is sufficient to cause CML	21
1.3 CML treatment.....	25
1.3.1 Non-specific therapies	25
1.3.2 Imatinib mesylate	26
1.3.3 Nilotinib & Dasatinib.....	29
1.4 IC50 and Intracellular Uptake and Retention assay (IUR)	29
1.5 OCT-1	32
1.6 ABCB1 and ABCG2.....	35
1.6.1 TKI interaction with ABCB1 and ABCG2	38
1.6.1.1 Imatinib	38
1.6.1.2 Nilotinib.....	39
1.6.1.3 Dasatinib.....	40
1.7 Haematopoietic Stem Cells	40
1.8 Mechanisms of resistance to TKIs.....	41
1.8.1 BCR-ABL expression induces genomic instability.....	41
1.8.2 BCR-ABL kinase domain mutations	44
1.8.3 Upregulation of TKI efflux proteins	49
1.8.4 BCR-ABL overexpression	50
1.8.4.1 Homogeneously staining regions and double minutes	51
1.8.5 BCR-ABL independent resistance	51
1.9 Generation of TKI resistance in vitro, and investigating the kinetics and interplay of resistance mechanism emergence	53
1.10 Hypothesis	55
1.11 Aims.....	55
Chapter 2:	56
Materials and Methods	56
2.1 Commonly used reagents.....	57
2.2 Solutions, buffers and media	57
2.2.1 Cell culture media	57

2.2.2 Tyrosine kinase inhibitors	58
2.2.2.1 Imatinib mesylate	58
2.2.2.2 Nilotinib	58
2.2.2.3 Dasatinib	58
2.2.2.4 100µM 14C-Imatinib mixture (50%)	58
2.2.2.5 100µM 14C-Dasatinib mixture (50%)	58
2.2.3 Prazosin hydrochloride – inhibits OCT-1	58
2.2.4 PSC833 – inhibits ABCB1	59
2.2.5 Ko143 – inhibits ABCG2	59
2.2.6 Flow cytometry Fixative (FACS Fix)	59
2.2.7 Freeze Mix	59
2.2.8 Laemmli’s Buffer	59
2.2.9 Membrane blocking solution (2.5%)	60
2.2.10 SDS-Polyacrylamide Gel	60
2.2.11 1xTBS	60
2.2.12 1xTBST	60
2.2.13 dNTP set (N = A, C, G, T)	60
2.2.14 Random Hexamer Primer	61
2.3 Cell lines	61
2.3.1 K562	61
2.3.2 K562 Dox	61
2.3.3 KU812	61
2.4 General Techniques	61
2.4.1 Tissue culture	61
2.4.2 Cell counts	62
2.4.3 Cryopreservation of cells	62
2.4.4 Thawing cells	62
2.5 Specialised Techniques	62
2.5.1 Generation of TKI resistant cell lines	62
2.5.1.1 Sampling intermediate lines for analysis	63
2.5.2 DNA extraction	63
2.5.3 Quantitative DNA PCR	64
2.5.4 mRNA extraction	65
2.5.5 cDNA synthesis	65
2.5.6 RQ-PCR: BCR-ABL transcript quantitation	66
2.5.7 Sequencing the BCR-ABL kinase domain	67
2.5.7.1 Conventional sequencing	69
2.5.7.2 MassARRAY sequencing (Sequenom)	69
2.5.8 RQ-PCR: Lyn transcript quantitation	71
2.5.9 IC50 assay and Western blot	73
2.5.10 Flow cytometry	73

2.5.10.1 Measurement of ABCB1/ABCG2 cell-surface expression	73
2.5.10.2 Cell viability	74
2.5.11 Intracellular Uptake and Retention (IUR) assay	75
2.5.12 Cytogenetic analysis	75
2.5.12.1 Fluorescence in situ hybridisation (FISH)	75
2.5.12.2 Karyotyping	77
2.5.13 Statistics.....	77
Chapter 3:.....	78
Imatinib resistance in the K562 cell line is mediated by BCR-ABL overexpression.....	78
3.1 Introduction	79
3.1.1 Adherence and dose-interruptions.....	79
3.1.2 Suboptimal kinase inhibition	79
3.1.3 Generation of imatinib-resistant cell lines	80
3.1.4 BCR-ABL overexpression	81
3.1.5 The K562 cell line	82
3.2 Approach	83
3.2.1 Generation of imatinib-resistant cell lines	83
3.2.2 Analysis of imatinib-resistant cell lines	88
3.3 Results	90
3.4 Discussion	107
Chapter 4:.....	111
Imatinib resistance in the K562 Dox cell line is mediated by ABCB1 overexpression.....	111
4.1 Introduction	112
4.1.1 The multidrug resistance protein, ABCB1.....	112
4.1.2 ABCB1 expression in CML	113
4.1.3 The breast cancer resistance protein, ABCG2	115
4.1.4 The K562 Dox cell line	116
4.2 Approach	117
4.2.1 Generating imatinib resistance in the K562 Dox cell line	117
4.2.2 Analysis of imatinib-resistant cell lines	118
4.3 Results	119
4.4 Discussion	134
Chapter 5:.....	137
BCR-ABL kinase domain mutations arise in the setting of BCR-ABL overexpression, in imatinib- and dasatinib-resistant cell lines	137
5.1 Introduction	138
5.1.1 BCR-ABL kinase domain mutations	138
5.1.2 BCR-ABL expression and kinase domain mutations.....	139

5.1.3 Conventional sequencing and the MassARRAY technique.....	140
5.1.4 The KU812 cell line	141
5.2 Approach	143
5.2.1 Generating dasatinib resistance in the K562 and K562 Dox cell lines	143
5.2.2 Generating imatinib resistance in the KU812 cell line	145
5.2.3 Re-escalation of intermediates in imatinib, dasatinib or nilotinib	146
5.2.4 Analysis of dasatinib- and imatinib-resistant cell lines.....	147
5.3 Results	150
5.3.1 Dasatinib resistance in the K562 cell line	150
5.3.2 Dasatinib-resistance in K562 Dox cell lines.....	156
5.3.2.1 The K562 Dox 200nM DAS1 cell line.....	156
5.3.2.2 The K562 Dox 200nM DAS2 cell line.....	164
5.3.3 Imatinib-resistance in KU812 cell lines	172
5.3.3.1 The KU812 2µM IM1 cell line	172
5.3.3.2 The KU812 3µM IM2 cell line	176
5.3.3.3 The KU812 2µM IM3 cell line	182
5.4 Discussion	192
5.4.1 BCR-ABL overexpression precedes the emergence of KD mutations	192
5.4.2 BCR-ABL expression levels significantly decrease upon the emergence of KD mutations	194
5.4.3 Kinetics of DAS-resistance development in the K562 200nM DAS cell line.....	195
5.4.4 A V299L-carrying clone emerged early on in DAS exposure in the K562 Dox cell line	198
5.4.5 Multiple KD mutations emerged in imatinib-resistant KU812 cell cultures	199
Chapter 6:.....	202
TKI cross-resistance and differential resistance in imatinib- and dasatinib-resistant CML cell lines	202
6.1 Introduction	203
6.1.1 TKI cross-resistance and differential resistance	203
6.1.2 BCR-ABL independent resistance: Src family kinases.....	203
6.2 Approach	205
6.3 Results	206
6.3.1 TKI cross-resistance in the K562 200nM DAS cell line	206
6.3.2 Differential TKI resistance and cross-resistance in the K562 Dox 200nM DAS1 and 2 cell lines.....	206
6.3.3 ABCB1 overexpression confers TKI cross-resistance in the K562 Dox 2µM IM1, IM2 and IM3 cell lines	210
6.3.4 BCR-ABL overexpression and KD mutations in the KU812 2µM IM1, 3µM IM2 and 2µM IM3 cell lines conferred differential or cross-resistance to TKIs	213
6.3.5 BCR-ABL and Lyn overexpression in the K562 2µM IM1 and IM2 cell lines conferred differential or cross-resistance to TKIs	213
6.4 Discussion	222

6.4.1 TKI-cross resistance	222
6.4.2 Differential resistance	224
6.4.3 Lyn overexpression in the K562 2 μ M IM2 cell line: Is it really a BCR-ABL-independent resistance mechanism?	225
Chapter 7:.....	226
Discussion	226
7.1 Introduction	227
7.2 TKI resistance mechanisms	227
7.3 Studying the kinetics of TKI resistance mechanism emergence.....	228
7.4 Major findings of this study	229
7.4.1 Kinase domain mutations arise in the setting of BCR-ABL overexpression.....	229
7.4.2 Resistance mechanism emergence is stochastic.....	230
7.4.3 Different TKIs may foster different resistance mechanisms	231
7.4.4 Different cell lines responded differently to a given TKI	232
7.4.5 TKIs share the same broad resistance susceptibilities.....	233
7.4.6 Src kinase overexpression may not be a BCR-ABL <i>independent</i> resistance mechanism ..	233
7.5 Future directions	234
7.6 Summary & Conclusion	234
Appendix I	236
AI.1 Quantitative DNA PCR setup sheet	237
AI.2 RQ-PCR for BCR-ABL quantitation setup sheet.....	238
AI.3 BCR-ABL mRNA quantitation setup sheet.....	239
AI.4 DNA sequence of the Abl gene	240
AI.5 Kinase domain mutations included in the MassARRAY sequencing screen.....	242
AI.6 Lyn quantitation setup sheet	243
AI.7 Western blots for Table 6.1: Dasatinib IC50s for the K562 Dox 200nM DAS1 cell line and intermediates	244
AI.8 Western blots for Table 6.1: Nilotinib IC50s for the K562 Dox 200nM DAS1 cell line and intermediates	245
AI.9 Western blots for Table 6.1: Imatinib IC50s for the K562 Dox 200nM DAS1 cell line and intermediates	246
AI.10 Western blots for Figure 6.4: Nilotinib IC50s for the K562 Dox 2 μ M IM1, IM2 and IM3 cell lines and Naïve controls.....	247
AI.11 Western blots for Figure 6.4: Nilotinib IC50s with PSC833 for the K562 Dox 2 μ M IM1, IM2 and IM3 cell lines and Naïve controls.....	248
AI.12 Western blots for Figure 6.4: Dasatinib IC50s for the K562 Dox 2 μ M IM1, IM2 and IM3 cell lines and Naïve controls	249
AI.13 Western blots for Figure 6.4: Dasatinib IC50s with PSC833 for the K562 Dox 2 μ M IM1, IM2 and IM3 cell lines and Naïve controls.....	250

AI.14 Western blots for Table 6.2: Imatinib IC50s for the KU812 2 μ M IM1 and 3 μ M IM2 cell lines and KU812 Naïve control	251
AI.15 Western blots for Table 6.2: Nilotinib IC50s for the KU812 2 μ M IM1 and 3 μ M IM2 cell lines and KU812 Naïve control	252
AI.16 Western blots for Table 6.2: Dasatinib IC50s for the KU812 2 μ M IM1 and 3 μ M IM2 cell lines and KU812 Naïve control	253
AI.17 Western blots for Table 6.3: Imatinib IC50s for the KU812 2 μ M IM3 cell line and intermediates	254
AI.18 Western blots for Table 6.3: Nilotinib IC50s for the KU812 2 μ M IM3 cell line and intermediates	255
AI.19 Western blots for Table 6.3: Dasatinib IC50s for the KU812 2 μ M IM3 cell line and intermediates	256
AI.20 Western blots for Figure 6.5 & 6.6: Nilotinib and dasatinib IC50s for the K562 2 μ M IM1 and IM2 cell lines	257

Appendix II

Publication arising from this thesis	258
---	------------

References	268
-------------------------	------------

List of Figures and Tables

Figure 1.1: The Philadelphia Chromosome	22
Figure 1.2: The Philadelphia chromosome and the BCR-ABL oncoprotein.....	23
Figure 1.3: Signal transduction pathways affected by BCR-ABL.....	24
Figure 1.4: Molecular structure of imatinib mesylate	27
Figure 1.5: Mechanism of action of imatinib	28
Figure 1.6: Molecular structure of nilotinib	30
Figure 1.7: Molecular structure of dasatinib.....	31
Figure 1.8: Protein structure of OCT-1 (SLC22A1).....	34
Figure 1.9: Protein structure of ABCB1 (MDR1; P-glycoprotein).....	36
Figure 1.10: Protein structure of ABCG2 (BCRP).....	37
Figure 1.11: Mechanisms of resistance to TKIs.....	42
Figure 1.12: The effects of BCR-ABL on mutagenesis.....	45
Figure 1.13: Map of BCR-ABL KD mutations.....	46
Figure 1.14: Nilotinib and dasatinib have different critical binding residues in the ABL kinase domain, compared to imatinib.....	47
Figure 1.15: Differential sensitivity of kinase domain mutations to the three TKIs – imatinib, nilotinib and dasatinib	48
Figure 3.1: The K562 Naïve cell line does not carry any BCR-ABL kinase domain mutations	84
Figure 3.2: ABCB1 cell-surface expression in the IM1 and IM2 resistant cell lines.....	86
Figure 3.3: ABCG2 cell-surface expression in the IM1 and IM2 resistant cell lines	87
Figure 3.4: Viability assay by trypan blue analysis: K562 Naïve versus K562 2µM IM1 & IM2 cell lines	91
Figure 3.5: Viability by Annexin V and 7AAD staining: K562 Naïve versus K562 2µM IM1 & IM2 cell lines	92
Figure 3.6: Example of a K562 Naïve IC ₅₀ ^{imatinib} Western blot quantification.....	93
Figure 3.7: IC ₅₀ ^{imatinib} of the K562 Naïve, K562 2µM IM1 and K562 2µM IM2 cell lines	95
Figure 3.8: Average IC ₅₀ imatinib for K562 Naïve, K562 2µM IM1 and K562 2µM IM2	96
Figure 3.9: Imatinib IUR assay: K562 Naïve cell line versus K562 2µM IM1 cell line	97
Figure 3.10: Imatinib IUR assay: K562 Naïve cell line versus K562 2µM IM2 cell line	98
Figure 3.11: Intermediate BCR-ABL expression in the IM1 and IM2 resistant cell lines	100
Figure 3.12: Interphase FISH to identify BCR-ABL fusion genes	101
Figure 3.13: Karyotype of the K562 Naïve cell line.....	102
Figure 3.14: Karyotype of K562 2µM IM1 and IM2 cell lines	103
Figure 3.15: Metaphase FISH to identify markers carrying Bcr-Abl.....	105
Figure 3.16: Bcr-Abl copy number in the IM1 and IM2 resistant cell lines.....	106

Figure 4.1: The development of a multidrug resistant (MDR) cancer	114
Figure 4.2: Intermediate BCR-ABL mRNA expression in the K562 Dox 2µM IM1, IM2 and IM3 cell lines	120
Figure 4.3: ABCG2 cell surface expression in IM-resistant K562 Dox cell lines.....	121
Figure 4.4: ABCB1 cell surface expression increased in the K562 Dox IM-resistant cell lines	122
Figure 4.5: K562 Dox IM-resistant cell lines have a reduced imatinib intracellular uptake and retention (IUR) compared to K562 Dox Naïve control cells	123
Figure 4.6: Example of a K562 Dox Naïve IC50 ^{imatinib} Western blot quantification	127
Figure 4.7: K562 Dox IM-resistant cell lines have increased IC50 ^{imatinib} compared to K562 Dox Naïve control cells	129
Figure 4.8: In the presence of PSC833, K562 Dox IM-resistant cell lines have similar IC50 ^{imatinib} values compared to K562 Dox Naïve control cells	131
Figure 4.9: PSC833 removes the significant difference in IC50 ^{imatinib} values between the three IM-resistant K562 Dox lines and Naïve controls	133
Figure 5.1: Karyotype of KU812 cell line when first established	142
Figure 5.2: Src-mediated pathways contribute to cancer progression.....	144
Figure 5.3: K562 DMSO IC50 ^{dasatinib} Western blot quantification	148
Figure 5.4: The K562 200nM DAS cell line has an increased IC50 ^{DAS} compared to the K562 Naïve and DMSO control cell lines	151
Figure 5.5: The average IC50 ^{DAS} for K562 200nM DAS was significantly greater than that of the K562 Naïve and DMSO control cell lines	152
Figure 5.6: The K562 200nM DAS cell line does not express ABCB1 or ABCG2	153
Figure 5.7: Dasatinib IUR does not differ between the K562 200nM DAS cell line and the K562 Naïve and DMSO control cell lines.....	154
Figure 5.8: BCR-ABL expression levels and KD mutation status in the K562 200nM DAS cell line ...	155
Figure 5.9: Bcr-Abl copy number in intermediates of the K562 200nM DAS cell line.....	157
Figure 5.10: Cell surface expression of ABCB1 or ABCG2 in the K562 Dox 200nM DAS1 cell line...	158
Figure 5.11: Dasatinib IUR does not differ between the K562 Dox 200nM DAS1 cell line and the K562 Dox Naïve control cell line.....	160
Figure 5.12: BCR-ABL expression increased until the emergence of the V299L mutation in a DAS-resistant K562 Dox cell line	161
Figure 5.13: Bcr-Abl copy number in selected intermediates of the K562 Dox 200nM DAS1 cell line	162
Figure 5.14: Interphase FISH to identify Bcr-Abl fusion genes	163
Figure 5.15: Cell surface expression of ABCB1 or ABCG2 in the K562 Dox 40nM and 55nM dasatinib re-escalation cell lines	165
Figure 5.16: The V299L mutation emerged when the K562 Dox 55nM DAS1 intermediate was re-escalated in dasatinib.....	166
Figure 5.17: The V299L mutation emerged when the K562 Dox 40nM DAS1 intermediate was re-escalated in dasatinib.....	167

Figure 5.18: There was no change in cell surface expression of ABCB1 or ABCG2 in the K562 Dox 500nM NIL re-escalation cell lines	168
Figure 5.19: Re-escalation of the K562 Dox 55nM intermediate in NIL resulted in the emergence of the G250E mutation or increased BCR-ABL expression	169
Figure 5.20: Cell surface expression of ABCB1 or ABCG2 in the K562 Dox 200nM DAS2 cell line...	170
Figure 5.21: Intermediate BCR-ABL expression levels in the K562 Dox 200nM DAS2 cell line	171
Figure 5.22: Cell surface expression of ABCB1 and ABCG2 in the KU812 2 μ M IM1 cell line	173
Figure 5.23: The imatinib IUR in the KU812 2 μ M IM1 cell line was not significantly different from the KU812 Naïve cell line, and was not affected by blocking ABCG2	174
Figure 5.24: BCR-ABL expression increased until the emergence of three KD mutations in the KU812 2 μ M IM1 cell line	175
Figure 5.25: Bcr-Abl DNA copy number was significantly increased in the KU812 2 μ M IM1 cell line compared to the KU812 Naïve cell line.....	177
Figure 5.26: Karyotype of the KU812 Naïve cell line	178
Figure 5.27: Karyotypes of the heterogeneous KU812 2 μ M IM1 population.....	179
Figure 5.28: Interphase FISH to identify Bcr-Abl fusion genes.....	180
Figure 5.29: BCR-ABL expression and KD mutation status in the KU812 3 μ M IM2 cell line	181
Figure 5.30: Bcr-Abl DNA copy number was significantly increased in the KU812 3 μ M IM2 cell line compared to the KU812 Naïve cell line.....	183
Figure 5.31: Interphase FISH to identify Bcr-Abl fusion genes.....	184
Figure 5.32: Cell surface expression of ABCB1 and ABCG2 in the KU812 3 μ M IM2 cell line	185
Figure 5.33: Cell surface expression of ABCB1 and ABCG2 in the KU812 2 μ M IM3 cell line	186
Figure 5.34: BCR-ABL expression increased until the emergence of the F359C mutation KU812 2 μ M IM3 cell line	187
Figure 5.35: Bcr-Abl DNA copy number did not significantly change in the KU812 2 μ M IM3 intermediates or final cell line compared to the KU812 Naïve cell line	188
Figure 5.36: Interphase FISH to identify Bcr-Abl fusion genes.....	189
Figure 5.37: The F359C mutation emerged when the KU812 200nM IM3 intermediate was re-escalated in imatinib.....	191
Table 5.1: Summary of resistance mechanisms detected in three TKI-resistant cell lines exposed to IM or DAS, as well as those detected in the re-escalated cell cultures.	193
Figure 5.38: Representations of possible clonal kinetics of resistance emergence	196
Figure 6.1: The K562 200nM DAS cell line displayed overt resistance to imatinib and nilotinib despite previous exposure to dasatinib only.....	207
Figure 6.2: The average IC ₅₀ ^{IM} and IC ₅₀ ^{NIL} for K562 200nM DAS was significantly greater than that of the K562 Naïve and DMSO control cell lines.....	208
Table 6.1: The K562 Dox 200nM DAS1 cell line has differential resistance to DAS, NIL and IM.....	209
Figure 6.3: The K562 Dox 200nM DAS2 cell line displayed overt resistance to dasatinib, imatinib and nilotinib despite previous exposure to dasatinib only.....	211

Figure 6.4: ABCB1 inhibition ablates NIL and DAS resistance in the three IM-resistant K562 Dox cell lines	212
Table 6.2: The IC_{50}^{IM} , IC_{50}^{NIL} and IC_{50}^{DAS} of the KU812 2 μ M IM1 and 2 μ M IM2 cell lines compared to the KU812 Naïve cell line.....	214
Table 6.3: The KU812 2 μ M IM3 cell line exhibits differential resistance to IM, NIL and DAS	215
Figure 6.5: Nilotinib IC_{50} and viability of the K562 2 μ M IM1 and IM2 cell lines	216
Figure 6.6: Dasatinib IC_{50} and viability of the K562 2 μ M IM1 and IM2 cell lines.....	219
Figure 6.7: Lyn kinase expression was significantly increased in the K562 2 μ M IM2 cell line	221
Table 6.4: Summary of resistance mechanisms detected in the eleven imatinib- or dasatinib-resistant cell lines generated in this study	223

Declaration

I, Carine Tang, certify that this thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent for this copy of my thesis, when deposited in the University Library, to be available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Carine Tang

1st September 2011

Acknowledgements

Romans 13:7 Render therefore to all their dues: tribute to whom tribute is due; custom to whom custom; fear to whom fear; honour to whom honour.

The past three and a half years have gone surprisingly fast! Time flies when you're having fun, and although I'm not sure 'fun' is the word I would use to describe doing a Phd, it has been a mostly enjoyable and incredibly rewarding experience.

Firstly I must thank Tim and Deb – my fantastic supervisors who have been consistently encouraging and supportive from day one. Your guidance, critique and ideas were essential for all of my achievements (exciting results, conference attendance, poster presentations and a publication.....or two?).

Many thanks also to the tireless team that is the Melissa White Laboratory: Eva, Chung, Tamara, Verity, Amity, Phuong, Kelvin, Jarrad, Jenny, Stephanie Z. You have all taught me something, helped me in some way, and patiently answered my many questions. Thanks also to Bron, Ljiljana, Sasha and especially Steph A. for all your work behind the scenes. I must also thank all the MWL students, past and present: Devendra, Jane, Jackie, Laura, Dale, Lisa, Oi-Lin and Liu. Thanks for the support, advice, camaraderie, and for the laughs (you know who you are).

My many tireless hours down in Molecular Pathology would have been much more difficult (and dull) if it wasn't for Susan Branford, Wendy, Jodi and Chani. Thank you so very much for teaching me many useful techniques, for being patient with me, and thanks to Sarah Moore for the incredibly useful karyotyping and FISH results!

Thanks to you Mum for getting me this far – for never giving up on my education, and for instilling in me a strong work ethic and drive for success.

What can I say about my darling Neptune? You have been there with me for many-a weekend tissue culture and late-night Western transfer, and you've never complained. I could not ask for anyone more encouraging, supportive and patient. Thank you for making me laugh whenever I needed it (which was all the time), and for just being you.

Lastly and most importantly, I thank the Lord Jesus Christ, my Creator and personal Saviour. To You belongs all the credit and glory.

Psalms 18:30 As for God, His way is perfect: the word of the LORD is tried: He is a buckler to all those that trust in Him.

Glossary

ABCB1/ABCG2	ATP binding cassette (ABC) transporter proteins B1 and G2
ALL	Acute lymphoblastic leukaemia
AP	Accelerated phase
APS	Ammonium persulfate
ATP	Adenosine triphosphate
BC	Blast crisis
BCR	Breakpoint cluster region
BCR-ABL	Breakpoint cluster region-Abl kinase fusion transcript/protein
Bcr-Abl	Breakpoint cluster region-Abl kinase fusion gene
C	Celsius
CCR	Complete cytogenetic response
CD	Cluster of differentiation
cDNA	Complementary deoxyribonucleic acid
CHO	Chinese hamster ovary
CHR	Complete haematologic response
CML	Chronic myeloid leukaemia
CP	Chronic phase
Crkl	CT10 regulator of kinase-like
DABCO	1,4-diazabicyclo[2.2.2]octane
DAS	Dasatinib
ddNTP	Dideoxynucleotide triphosphate
DEPC	Diethyl pyrocarbonate
DMSO	Dimethyl sulphoxide
dmin	Double minutes
DNA	Deoxyribonucleic acid
dNTP	Deoxynucleotide triphosphates
DTT	Dithiothreitol
FACS	Fluorescence activated cell sorting
FISH	Fluorescent <i>in situ</i> hybridisation

GUSB	Beta-glucuronidase
HBSS	Hanks Balanced Salt Solution
Hck	Haemopoietic cell kinase
HCl	Hydrochloric acid
HSR	Homogenously staining region
IC50	Inhibitory concentration 50%
IgG	Immunoglobulin G
IM	Imatinib mesylate
JAK	Janus kinase
KD	Kinase domain
kD	Kilo Dalton
KDR	Kinase insert domain protein receptor
L	Litre
Lyn	V-yes-1 Yamaguchi sarcoma viral related oncogene homolog
M	Molar (Moles per litre)
Mbq	Mega Becquerel (10^6 Becquerel)
MCR	Major cytogenetic response
MDR	Multidrug resistance
μCi	Micro Curie (10^{-6} Curie)
μg	Micro gram (10^{-6} gram)
μM	Micro molar (10^{-6} Molar)
MMR	Major molecular response
mM	Milli molar (10^{-3} Molar)
mRNA	Messenger ribonucleic acid
NHEJ	Non-homologous end-joining
NIL	Nilotinib
nM	Nano molar (10^{-9} Molar)
OCT-1	Organic cation transporter 1
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
Ph	Philadelphia chromosome

PI3-K	Phosphatidylinositol – 3-kinase
P-loop	Phosphate binding loop
PVDF	Polyvinylidene Fluoride
P-value	Probability value
RANKL	Receptor activator of nuclear factor kappa-b ligand
RNA	Ribonucleic acid
ROC	Receiver operating characteristic
RPMI	Roswell Park Memorial Institute (-1640 medium)
RT	Room temperature
RQ-PCR	Real-time quantitative polymerase chain reaction
SD	Standard deviation
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM	Standard error of the mean
SH	Src Homology domain
SN	Supernatant
Src	Sarcoma
SSC	Saline-Sodium Citrate buffer
TBS	Tris buffered saline
TBST	Tris buffered saline with 0.1% Tween20
TKI	Tyrosine kinase inhibitor
Tris	Tris(hydroxymethyl)aminomethane
UV	Ultra violet

Abstract

Chronic myeloid leukaemia (CML) is characterised by the presence of the Philadelphia chromosome which harbours the Bcr-Abl oncogene. BCR-ABL is a constitutively active tyrosine kinase that can be inhibited by rationally designed tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib and dasatinib. Although TKI therapy is an effective treatment for many patients, resistance can arise. There are currently four identified resistance mechanisms. These are 1) overexpression of drug-efflux proteins (ABCB1 and ABCG2), 2) BCR-ABL kinase domain (KD) mutations, 3) increased BCR-ABL expression and 4) BCR-ABL independent mechanisms such as Lyn kinase expression. In this study the interplay between these four recognised modes of TKI resistance is investigated.

Imatinib- and dasatinib-resistant cell lines were established and used to investigate TKI resistance *in vitro*. Viability and IC₅₀ assays were used to demonstrate TKI sensitivity/resistance. Flow cytometry was used to screen for ABCB1 and ABCG2 cell surface expression, while conventional sequencing and the MassARRAY method were used to determine the mutation status of the BCR-ABL KD. Fluorescence *in situ* hybridisation (FISH) and quantitative DNA PCR were used to investigate Bcr-Abl DNA copy number, and RQ-PCR was used to investigate expression levels of BCR-ABL and Lyn mRNA.

These studies revealed that IM-resistant K562 cell lines exhibited increased BCR-ABL expression at the onset of resistance. Interestingly, these cell lines had increased viability and IC₅₀s for IM and NIL, while the DAS IC₅₀s were variable. Further investigation revealed Lyn overexpression in the cell line which was more sensitive to DAS. The development of a DAS-resistant K562 culture resulted in the emergence of the T315I mutation. Studies of the intermediate stages of resistance of this DAS-resistant cell line revealed that increased BCR-ABL expression occurred gradually, preceding the emergence of the mutation, at which time the BCR-ABL expression decreased and plateaued. Thus, it appears that increased BCR-ABL expression may be the initial mechanism of resistance, followed by the emergence of a KD mutation which has a clear selective advantage. This phenomenon was observed a further four times (in a DAS-resistant K562 Dox culture, and in three IM-resistant KU812 cultures) each time with the emergence of different KD mutations. Different KD mutations resulted in differential resistance to the three TKIs used in this study.

In contrast, three IM-resistant K562 Dox cell lines were not found to have any KD mutations, nor BCR-ABL overexpression. Instead, the primary cause of resistance in these lines appeared to be an increase in ABCB1 expression. The addition of PSC833 (an ABCB1 inhibitor) decreased the IM, NIL, and DAS IC50s for all three resistant lines to the level of the naïve control. This indicated that ABCB1 expression, facilitating active efflux of the drugs, is the primary mechanism of resistance in these lines.

This study demonstrates that KD emergence is a stochastic event, as the same mutation did not always occur twice when exposed to the same TKI. However, increased ABCB1 expression was more likely to arise recurrently in the predisposed K562 Dox cell line. Notably, different TKIs elicited different resistant mechanisms, and all but one (the Lyn overexpressing K562 cell line) were BCR-ABL dependent. Furthermore, all resistant cell lines showed cross-resistance (at least to some extent) to the three TKIs tested, suggesting that currently available TKIs share the same susceptibilities to drug resistance.